Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone972-3765-8585
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$710,000.00
Profitability
Miscellaneous
Employees101
OptionableOptionable
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.07. The biotechnology company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $7.80 million. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 brokerages have issued 1 year price targets for Compugen's stock. Their forecasts range from $9.00 to $9.00. On average, they expect Compugen's stock price to reach $9.00 in the next year. This suggests a possible upside of 183.9% from the stock's current price. View Analyst Price Targets for Compugen.
What is the consensus analysts' recommendation for Compugen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.
Has Compugen been receiving favorable news coverage?
Headlines about CGEN stock have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Compugen earned a coverage optimism score of 0.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Twist Bioscience (TWST), NanoString Technologies (NSTG), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI), Gritstone Oncology (GRTS), Mesoblast (MESO), Agenus (AGEN), DBV TECHNOLOGIE/S (DBVT), Nightstar Therapeutics (NITE), Scholar Rock (SRRK), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Krystal Biotech (KRYS), Replimune Group (REPL) and Avrobio (AVRO).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
- Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
- Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
- Dr. Zurit Levine, VP of Research & Discovery (Age 51)
- Dr. John J. Hunter Ph.D., VP of Antibody R&D (Age 56)
Who are Compugen's major shareholders?
Compugen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Cornerstone Investment Partners LLC (0.03%).
Which institutional investors are buying Compugen stock?
CGEN stock was acquired by a variety of institutional investors in the last quarter, including Cornerstone Investment Partners LLC.
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.17.
How big of a company is Compugen?
Compugen has a market capitalization of $162.60 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
What is Compugen's official website?
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
